Global Statistics

spot_img

Danielle Garcia

A proactive, determined and intra-entrepreneur, Garcia has more than 10 years of experience in the areas of medical and pharmaceutical communication, press relations, organizational communication and digital marketing. Garcia is also an experienced people manager and, with a focus on oncology and hematology, she provides targeted training and presentations (webinars) in all aspects of (bio-) pharmaceutical manufacturing.
Author's Latest

‘Eureka Moment’ in Tumor Treatment: Nearly One in Five People Diagnosed with Cancer wiling to Choose an Innovative Therapy

Results from a national survey from Roswell Park Comprehensive Cancer Center seem to suggest that nearly one in five people diagnosed with cancer prefer...

SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors

New preclinical data from Verismo Therapeutics' lead clinical pipeline, SynKIR™-110, targeting mesothelin in solid tumors, were presented at the Society of Immunotherapy of Cancer...

SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors

During the Society of Immunotherapy of Cancer (SITC) 2025 Annual Meeting, held November 5 – 9 at the Gaylord National Resort and Convention Center in...

Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain Receive the 2025 Merkin Prize

The 2025 Richard N. Merkin Prize in Biomedical Technology was jointly awarded to Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain in a ceremony...

SITC 2025: Parker Institute for Cancer Immunotherapy to Showcases Latest Advances in Immunotherapy

During the Society of Immunotherapy of Cancer (SITC) 2025 Annual Meeting, held November 5 – 9 at the Gaylord National Resort and Convention Center in...

Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033

According to the latest analysis by DataM Intelligence, the Next-Generation Multiple Myeloma Therapies Market Size was valued at USD 22.03 billion in 2023, increased to USD 23.13 billion in...

Grit Biotherapeutics to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801

Grit Biotherapeutics, a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an...

Eric Smith, and Andrew Aguirre Receive Michael F. Price Memorial Grant

The DeGregorio Family Foundation, with support from the Torrey Coast Foundation, has awarded a $750,000 Michael F. Price Memorial Grant to Eric Smith, MD,...

Orna Therapeutics to Present Study Results Supporting its in vivo CAR Programs for Autoimmune Diseases

Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, today announced upcoming presentations at the 67th American Society...

Recordati Rare Diseases to Share New Data at the American Society of Hematology (ASH) Meeting

Recordati Rare Diseases Inc. today announced the presentation of new data related to its growing portfolio of treatments for rare hematologic disorders at the...

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting...

Human T Cell Leukopak Isolation Kit Successfully Utilized by LEAH Labs and the University of Missouri to Treat Canine Cancer

Akadeum Life Sciences is pleased to announce the completion of the first treatment for canine cancer using cells isolated with their Human T Cell...

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Four biomedical innovators — Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain — have been jointly awarded the 2025 Richard N. Merkin Prize in Biomedical...

IASO Bio Partners with Korea’s GC Cell to Bring CAR-T Therapy to Korea

Nanjing IASO Biotechnology has signed an agreement with Korea's GC Cell to introduce the CAR-T therapy Equecabtagene Autoleucel (Fucaso®) to the South Korean market...

- A word from our sponsors -

spot_img

Follow us

HomeAuthorsPosts by Danielle Garcia

The Journal of CAR T-Cell Therapy is an international science & medicine-focused news publication designed to serve the needs of a diverse community, including academia, life sciences, pharma, clinical research, clinicians, and physicians. Along with global clinical and regulatory news, we also cover payor and policy-related news and updates.

© Copyright 2025 Sunvalley Communication, LLC

Quick Links

Must Read

Popular Articles